MedTrace Logo

Guanfacine for the Treatment of Spatial Neglect and Impaired Vigilance

NCT00955253 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2020-01-21

Study results available
· View outcomes & findings →

Summary

To find out if spatial neglect following stroke and brain injury can be reduced using guanfacine, a drug that was shown to improve neglect in two stroke patients in a previous pilot study (Malhotra et al, 2006). In this trial, the effects of guanfacine will be examined in a larger number of patients, and there will also be a systematic assessment of whether the drug is only effective in patients with particular patterns of brain damage.

Conditions

Interventions

DRUG

Guanfacine

2mg oral guanfacine (encapsulated)

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Wellcome Trust

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Paresh A Malhotra, PhD MRCP · Imperial College London

  • Masud Husain, DPhil FRCP · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2014-03-28
Completion
2014-03-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955253 on ClinicalTrials.gov